IRIS PubliCatt

Armuzzi, Alessandro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.998
NA - Nord America 5.279
AS - Asia 1.363
AF - Africa 29
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 18
SA - Sud America 9
Totale 13.720
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.252
DE - Germania 3.469
SE - Svezia 1.107
CN - Cina 731
IT - Italia 640
UA - Ucraina 514
IE - Irlanda 332
SG - Singapore 278
FR - Francia 273
GB - Regno Unito 217
FI - Finlandia 144
IN - India 133
RU - Federazione Russa 115
TR - Turchia 115
PL - Polonia 52
IR - Iran 30
BE - Belgio 29
JP - Giappone 25
AU - Australia 22
CI - Costa d'Avorio 18
CA - Canada 17
CZ - Repubblica Ceca 17
NL - Olanda 17
EU - Europa 15
ES - Italia 14
CH - Svizzera 13
HK - Hong Kong 13
PT - Portogallo 10
IL - Israele 8
KR - Corea 8
BR - Brasile 7
AT - Austria 5
EG - Egitto 5
HU - Ungheria 5
MX - Messico 5
BG - Bulgaria 4
BZ - Belize 4
MO - Macao, regione amministrativa speciale della Cina 4
RO - Romania 4
RS - Serbia 4
GR - Grecia 3
IQ - Iraq 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
NZ - Nuova Zelanda 2
PK - Pakistan 2
A1 - Anonimo 1
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AZ - Azerbaigian 1
BT - Bhutan 1
DK - Danimarca 1
DZ - Algeria 1
EE - Estonia 1
HR - Croazia 1
ID - Indonesia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
MA - Marocco 1
MD - Moldavia 1
MK - Macedonia 1
MY - Malesia 1
NG - Nigeria 1
PA - Panama 1
PH - Filippine 1
SC - Seychelles 1
TN - Tunisia 1
UG - Uganda 1
VE - Venezuela 1
VN - Vietnam 1
Totale 13.720
Salva come PNG Salva come JPEG
Città #
Chandler 1.277
Cologne 1.211
Ashburn 436
Dublin 324
Jacksonville 321
San Mateo 264
Singapore 179
Nanjing 171
New York 164
Ann Arbor 147
Wilmington 141
Dearborn 134
Milan 131
Cattolica 123
Nürnberg 119
Boston 113
Beijing 112
Princeton 107
Munich 101
Izmir 100
Chicago 82
Marseille 82
Moscow 73
Rome 63
Houston 62
Bremen 61
Essen 61
Nanchang 59
Woodbridge 59
Lawrence 57
Los Angeles 55
Seattle 54
Redwood City 53
Fairfield 44
Lancaster 43
Hangzhou 41
Boardman 39
Pune 39
Norwalk 38
Helsinki 36
Kraków 35
Mountain View 35
Hebei 34
Shenyang 31
Brussels 26
Jiaxing 26
Tianjin 26
University Park 26
Augusta 24
Leawood 23
Kunming 22
Changsha 20
Abidjan 18
Detroit 18
Zhengzhou 18
Shanghai 17
Fremont 16
Jinan 15
Washington 15
San Jose 14
Andover 13
Kish 13
Redmond 13
Warsaw 13
Guangzhou 12
Hong Kong 10
Zurich 10
Brno 9
Costa Mesa 9
Edinburgh 9
Hefei 9
Tokyo 9
Ardabil 8
Busto Arsizio 8
Cagliari 8
Campagna 8
Istanbul 8
Lappeenranta 8
Seoul 8
Simi Valley 8
Toronto 8
Amsterdam 7
Atlanta 7
Cambridge 7
Lanzhou 7
London 7
Buffalo 6
Changchun 6
Indiana 6
Las Vegas 6
Lisbon 6
Millbury 6
Monmouth Junction 6
Sacramento 6
San Diego 6
Ferrara 5
Madrid 5
Paris 5
Prineville 5
Tomsk 5
Totale 7.550
Salva come PNG Salva come JPEG
Nome #
3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and medical management 1.303
A) Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. 315
A) Infliximab in the treatment of steroid-dependent ulcerative colitis. 250
A) Lack of endoscopic visualization of intestinal villi with the "immersion technique" in overt atrophic celiac disease 205
13C-methionine breath tests for mitochondrial liver function assessment. 201
13C-breath tests in the study of microsomal liver function 191
Sacroileitis and peripheral arthropathy associated with ulcerative colitis: effect of infliximab on both articular and intestinal symptoms 191
Growth hormone in inflammatory bowel disease 179
Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study 169
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 150
134C-breath tests in the study of mitochondrial liver function 148
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 141
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 140
13C-breath tests in the study of microsomial liver function 136
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 134
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 133
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 133
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 130
Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in different populations. 128
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. 127
13C-methionine breath tests for mitochondrial liver function assessment 122
Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab 120
A) Advances in extracorporeal detoxification by MARS dialysis in patients with liver failure 118
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 117
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 110
13C-breath tests in the study of mitochondrial liver function 110
Delta13CO2 excretion and expression of dyspeptic symptoms in patients evaluated for Helicobacter pylori infection by [13C] urea breath test 110
Helicobacter pylori infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria 109
Levofloxacin based regimens for the eradication of Helicobacter pylori 104
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. 104
ag) Fecal calprotectin in first-degree relatives of patients with ulcerative colitis. 103
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 102
Ileal Crohn's disease: CEUS determination of activity 101
Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? 101
Fecal calprotectin in first-degree relatives of patients with ulcerative colitis 95
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 95
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. 95
Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy 95
Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study 94
Efficacy and tolerability of antibiotics in patients undergoing H. pylori eradication 93
A) Antibodies to Saccharomyces cerevisiae: are they useful in clinical practice? 91
-Can 13C urea breath test predict resistance to therapy in Helicobacter pylori infection? 91
Helicobacter pylori CagA-positive strains affect oxygen free radicals generation by gastric mucosa 91
Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update 89
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 89
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 88
Probiotics and Helicobacter pylori eradication 86
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 85
Helicobacter pylori treatment: a role for probiotics? 84
A novel pathogenic role for microvasculature in inflammatory bowel disease. 84
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test. 83
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. 81
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 81
[Helicobacter pylori and gastric carcinoma] 80
A) Study of liver function in healthy elderly subjects using the 13C-methacetin breath test 79
13C-methacetin breath test for monitoring hepatic function in cirrhotic patients before and after liver transplantation. 78
Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. 77
Infliximab in Crohn's disease: early and long-term treatment. 76
Gender affects 13C-ketoisocaproic acid breath test 75
Review article: breath testing for human liver function assessment. 73
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab 73
Management of perianal fistulas in Crohn's disease: an up-to-date review 72
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 72
Clinical trials in ulcerative colitis: a historical perspective 70
Signs of dissociation and symptoms of post-traumatic stress disorder in inflammatory bowel disease. A case-control study 70
Mucosal healing in ulcerative colitis: surveillance or colectomy? 68
Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. 68
Characterization of Sarcopenia in an IBD Population Attending an Italian Gastroenterology Tertiary Center 68
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment 67
Biological therapies for inflammatory bowel disease: research drives clinics. 66
anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab 65
Challenges in crohn’s disease management after gastrointestinal cancer diagnosis 65
A) Quantitative evaluation of liver function by the methionine and aminopyrine breath tests in the early stages of liver transplantation 64
Adalimumab in active ulcerative colitis: a "real-life" observational study 64
Multiparametric Evaluation Predicts Different Mid-Term Outcomes in Crohn's Disease 64
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 63
Saccharomyces cerevisiae-associated diarrhea in an immunocompetent patient with ulcerative colitis 63
Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease. 63
Reply to Dr. Joob et al.'s letter 63
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease 63
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 63
Inducing remission of ulcerative colitis: are clinicians better equipped than ever? 62
Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease 61
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 60
Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease 59
Epidemiology of inflammatory bowel disease in the Republic of San Marino: The “EPIMICI – San Marino” study 58
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases 58
Personalized Clinical Phenotyping through Systems Medicine and Artificial Intelligence 58
Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease 57
The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases 57
Frontiers in drug research and development for inflammatory bowel disease 57
Italian IBD Patients Coping With Covid-19 Emergency: The Mitigating Role of Psychological Readiness to Engage in Self-care 57
TRPM7 Is Overexpressed in Human IBD-Related and Sporadic Colorectal Cancer and Correlates with Tumor Grade 55
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy 55
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test 54
Adalimumab in the treatment of immune-mediated diseases 54
Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach 54
Personalized clinical phenotyping through systems medicine and artificial intelligence 54
Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study 53
Promoting psycho-social wellbeing for engaging inflammatory bowel disease patients in their care: an Italian consensus statement 53
Totale 10.733
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.914
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.914
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.107 0 0 103 50 122 150 130 80 103 57 179 133
2020/20211.103 71 106 18 132 132 44 94 28 149 64 242 23
2021/20221.510 97 120 28 178 43 48 23 246 45 94 269 319
2022/20233.459 421 441 239 540 266 394 163 302 413 98 117 65
2023/20243.061 79 490 61 108 88 270 95 1.196 214 81 179 200
2024/2025174 67 107 0 0 0 0 0 0 0 0 0 0
Totale 13.940